Fortis Hiranandani Hospital Vashi Launches Advanced Robotic Surgery Program
(L-R) Dr S. Narayani, Dr Roji Phillip, Mr Nitin Kamaria, Mr Anil Vinayak, Dr Jignesh Gandhi & Dr Shishir Shetty at the launch of Fortis Vashi's Advanced Robotic Surgery Program
The robotic surgical unit will be assisting in the precise and accurate control of endoscopic instruments including rigid endoscopes, blunt and sharp endoscopic dissectors, scissors, forceps/ pick-ups, needle holders, electrosurgery, and accessories for endoscopic manipulation of tissue, including grasping, cutting, blunt and sharp dissection, approximation, ligation, electrosurgery and suturing. Robotic-assisted surgery offers numerous benefits for both patients and surgeons. It enables greater precision, enhancing the surgeon's capabilities, allowing for more accurate and controlled movements, even in complex procedures. Being minimally invasive, it involves smaller incisions, resulting in less pain, reduced blood loss, and minimal scarring. Patients often benefit from faster recovery, with shorter hospital stays and quicker return to daily activities. The lower risk of complications is another key advantage, as enhanced visualization and precision helps reduce the chances of surgical errors & postoperative issues. Overall, improved outcomes are a hallmark of robotic surgery, leading to better clinical results, higher patient satisfaction, and an improved quality of life.
This initiative is closely aligned with Fortis' larger goal of becoming a center of excellence for high-end technology-driven healthcare. By integrating cutting-edge surgical innovations, Fortis Hiranandani Hospital Vashi continues to raise the benchmark for quality care while ensuring that patients in Navi Mumbai and beyond have access to world-class treatment options, closer to home.
Talking about the launch, Mr Nitin Kamaria, Facility Director, Fortis Hiranandani Hospital, Vashi, said, 'We have bolstered our robot-aided infrastructure by enabling the Versius advanced robotic technology for surgical procedures performed across specialties. By combining the precision of robotics with the surgeon's expertise, we're able to offer patients safer, faster, and more effective procedures, all the while ensuring our patients benefit from world-class medical care. Our goal is to continuously elevate healthcare standards. Through our Robotic Program, we reaffirm our vision to stay at the forefront of medical excellence, equip our specialists with best-in-class tools, and enhance the overall patient experience.'
Members of the community, clinicians, and the hospitals administrative staff were joined by Dr. S. Narayani, Business Head – Fortis Hospitals Maharashtra, for the inauguration of the Robotic Surgery Program.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
3 days ago
- The Hindu
250 grams of mangoes instead of bread for breakfast led to improved glycaemic control in diabetics
A small study carried out for two months involving 35 participants with type-2 diabetes has found that daily consumption of 250 grams of mango pulp and 200 ml of toned milk for breakfast resulted in improved glycaemic control, weight loss, reduced waist circumference, and improved insulin sensitivity compared with the control group. The control group had 81 grams of white bread and 200 ml of toned milk. Results of the study were published recently in the Journal of Diabetes & Metabolic Disorders. The serving size of mango was chosen based on macronutrient content to ensure equicaloric comparison with the control group. Blood glucose levels, body weight, anthropometric measures, and lipid profile of all 35 participants were measured before and after two months of the study. The participants were split into three groups — two treatment groups and one control group. The two treatment groups had 10 participants each — one group was served Safeda (Banganapalli) mango pulp, while the other treatment group was served Dasheri mango pulp. The control group with 15 participants consumed 81 grams of white bread. Lunch and dinner for both the treatment and control groups was a standard equicaloric diet as advised by guidelines for Asian Indians. Lunch and dinner for participants in the treatment and control groups were rich in vegetables and fruits, whole-grain, high-fibre foods, low-fat dairy products, limited foods containing partially hydrogenated vegetable oils, less sugar-sweetened beverages and foods with added sugar, reduced salt intake and no alcohol. One of the main reasons why participants in the treatment groups showed improved glycaemic control is because of the relatively less glycaemic index of mango compared with white bread. Food items with lower glycaemic index are less likely to significantly spike blood sugar levels when consumed in moderation. In addition, the fibre content in mangoes contributes to slower glucose absorption. 'The relatively lower glycaemic index and fibre content in mangoes is the reason why there is better blood glucose control and reduced insulin resistance compared with the group that had white bread, which is carbohydrate,' says Dr. Anoop Mishra, Chairman, Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, Chirag Enclave, New Delhi, and the corresponding author of the paper. 'It is important to note that a finite and small serving of mangoes should be a replacement for carbohydrates. Diabetics should not consume mangoes in addition to normal diet,' he says. 'The glycaemic index of mango is low to moderate — from 51 to 56 — while it is around 75 for white bread,' says Dr. Sugandha Kehar from the Diabetes Foundation (India), New Delhi, and the first author of the paper. 'The sweetness of mangoes is wrongly perceived to elevate our blood glucose levels. We fail to realise or take into account the low-moderate glycaemic index of mangoes. We incorporate white bread and other refined carbohydrates in our diet without realising the adverse effects, particularly the relatively high glycaemic index.' Participants in the intervention group were served 250 grams of mango pulp for breakfast each day for the entire duration (two months) of the study. According to Dr. Kehar, there is no difference between eating fresh mango and mango pulp. Mango pulp was used in the study to ensure compliance and to ensure participants had only 250 grams of mango each day for two months. The control group who consumed white bread showed significant increases in fasting blood glucose levels and HbA1c, while participants in the intervention group (both mango varieties) had lower fasting blood glucose levels and HbA1c. Participants in the intervention group (both mango varieties) demonstrated improvements in insulin sensitivity compared with the control group. There was reduction in body weight, BMI and waist circumference among participants who consumed mangoes compared with those who consumed white bread. Importantly, the average blood sugar level for the day among participants who consumed mangoes was less compared with participants who consumed white bread. 'A better glucose profile after breakfast can help maintain better blood sugar levels throughout the day,' says Dr. Mishra. This is where substituting carbohydrates with a limited portion (about 250 grams) of mangoes for breakfast will help diabetics better control their blood glucose levels. While blood glucose levels, anthropometric measurements, weight and BMI were measured by the researchers before the start and end of the study, daily blood glucose levels were measured by the participants using a glucometer and daily food intake details were also recorded by the participants. The study has some limitations. Besides being small in size, the duration of the study was only for two months. Larger studies for a longer duration are necessary to confirm the benefits of limited consumption of mangoes for breakfast instead of carbohydrates. Pilot study The team had undertaken a pilot study to test the effectiveness of mangoes in reducing blood glucose levels. The pilot study tested both diabetics and non-diabetics. In the first part of the pilot study, the oral tolerance test two hours after breakfast consisting of 250 grams of mangoes (three varieties) for the intervention group and white bread for the control group was studied. The study included 25 non-diabetics and 20 type-2 diabetics. Mangoes were found to produce similar or lower (non-significant) glycaemic responses in both diabetics and non-diabetics. In the second part of the pilot study, blood glucose was monitored continuously for three days. The study included 25 non-diabetics and 25 type-2 diabetics. Mangoes (250 grams) for breakfast produced similar glycaemic responses as bread in the case of non-diabetics. However, in the case of diabetics, the harmful glucose variation was significantly lower in participants who consumed mangoes (intervention group) compared with the control group (white bread).
Business Standard
5 days ago
- Business Standard
Fortis Healthcare hits all-time high after Q1 PAT climbs 57% YoY to Rs 260 cr
Fortis Healthcare jumped 4.38% to Rs 895.30 after the company reported a 56.83% surge in consolidated net profit to Rs 260.28 crore in Q1 FY26, compared to Rs 165.96 crore in Q1 FY25. Revenue from operations rose 16.55% year-on-year (YoY) to Rs 2,166.72 crore in the quarter ended 30 June 2025. Profit before exceptional items and tax stood at Rs 337.94 crore in Q1 FY26, up 47.02% from Rs 229.85 crore in the same quarter last year. The company also reported exceptional gains of Rs 12.63 crore in Q1 FY26. Operating EBITDA stood at Rs 491 crore, reflecting a 43.2% growth compared to Rs 343 crore in Q1 FY25. Operating EBITDA margin improved to 22.6% from 18.4% in the year-ago quarter. In Q1 FY26, revenue from the hospital business grew 18.6% to Rs 1,838 crore, up from Rs 1,549 crore in Q1 FY25. This growth was driven by a higher ARPOB (Average Revenue Per Occupied Bed) and a 7.8% increase in occupied beds compared to the previous year. The occupancy rate for the hospital business stood at 69% in Q1 FY26, up from 67% in Q1 FY25. ARPOB rose 9.95% to Rs 2.65 crore per annum, compared to Rs 2.41 crore per annum last year. The Average Length of Stay (ALOS) declined to 4.09 days from 4.16 days. International Patient revenues grew 17% to Rs 132 crore in Q3 FY25 as against Rs 113 crore in Q3 FY24. The business contributed 7.7% to overall hospital business revenues, similar the corresponding previous period. International patient revenues grew 21% to Rs 154 crore in Q1 FY26, up from Rs 127 crore in Q1 FY25. The segment contributed 7.9% to the hospital business revenues, slightly up from 7.8% in Q1 FY25. Key surgical procedures showed strong growth: Robotic surgeries rose 75%, radiation therapy increased 53%, and orthopedic procedures grew 22% year-on-year. Digital channels, including the website, mobile app, and digital campaigns, saw a 16.8% YoY increase in revenue contribution. These channels accounted for 29.5% of overall hospital revenues, compared to 29.9% in Q1 FY25. The diagnostic business gross revenue rose 7.4% to Rs 368.8 crore in Q1 FY26 from Rs 343.5 crore in Q1 FY25. Operating EBITDA margin, based on gross revenues, stood at 23.0%, up from 16.1% in the previous year. Excluding one-offs, the margin was 18.7% in Q1 FY25. During the quarter, Agilus Diagnostics conducted approximately 10.13 million tests, up from 9.57 million tests in Q1 FY25. In July 2025, Fortis signed an Operations and Maintenance Services (O&M) agreement with Gleneagles India. Under the agreement, Fortis will manage around 700 beds across five hospitals and one clinic in the Gleneagles network. As of 30 June 2025, the companys net debt stood at Rs 1,869 crore, with a Net Debt to EBITDA ratio of 0.92x, compared to 0.22x as of 30 June 2024 (based on Q1 annualized EBITDA). Net Debt to Equity rose to 0.20x from 0.04x in the prior year. Dr Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, We have witnessed a healthy start to the financial year, as demonstrated in our Q1 earnings for both hospital and diagnostic businesses. The recently executed O&M services agreement with Gleneagles India expands our geographic footprint and provides an opportunity to leverage our combined strengths to optimize operations and enhance efficiencies. The company also consummated the acquisition of Shrimann Superspecialty Hospital in Jalandhar, further strengthening our presence in Punjab region with approx. 1,000 beds. He further added In the diagnostics business, we have witnessed a strong recovery in both revenues and EBITDA margins which is reflective of the brand building initiatives undertaken over the last few quarters. We expect this growth momentum to continue going forward. Fortis Healthcare is a leading integrated healthcare delivery service provider in India. Its verticals include hospitals, diagnostics, and day care specialty facilities. As of now, the company operates 33 healthcare facilities (including JVs and O&M facilities) across 11 states, with a network of over 5,700 operational beds and 400 diagnostics labs. The scrip hit 52 week high at Rs 904.75 in intraday today.
Hindustan Times
03-08-2025
- Hindustan Times
Mohali Fortis told to pay ₹50 lakh for patient's death due to negligence
Finding Fortis hospital in Mohali guilty of gross medical negligence, the district consumer disputes redressal commission has directed it to pay ₹50 lakh compensation to the family of a patient who died at the hospital in 2021. The consumer commission held that the hospital is liable not only for medical negligence but also for deficiency in services and unfair trade practices. (Getty Images/iStockphoto) The deceased, Harit Sharma, was a practising advocate at the Punjab and Haryana high court. His dying declaration from the hospital bed, a note in which he had written that he overheard doctors discussing that his case was mishandled, served as a crucial piece of evidence. The consumer commission held that the hospital is liable not only for medical negligence but also for deficiency in services and unfair trade practices. 'The ends of justice would meet if a lump sum compensation of ₹50 lakh is awarded to the complainants in lieu of the medical negligence committed by the hospital,' said the commission. The complainants included the deceased's wife Priyanka Sharma and her two minor sons. They stated before the commission that Sharma had been admitted at the Fortis Hospital, Mohali, on the morning of July 28, 2021, as he suffered from acute gastric problem. He was treated by Mohnish Chabra and other attending doctors. Before admitting him, Fortis conducted a Covid test which was found negative. It is further pleaded that as the visiting hours were restricted, the victim's wife only went to meet him between 12.30pm to 1pm on July 29, 2021. She was told that her husband had recovered from the gastric problem and due to improvement, the patient desired to be shifted to a private ward from ICU. However, he was kept in ICU on the pretext that ascites – a medical condition characterised by the excessive accumulation of fluid in the abdominal cavity – was to be removed from his stomach. It was further stated that due to negligent tapping, his oxygen levels came down drastically and he had to be put on oxygen support. The victim's wife stated that Sharma was fully conscious despite being on oxygen support and he overheard the hospital director saying that the tapping was done wrongly and that it had to be re-done. The victim revealed this to the complainant through a written note – he was unable to speak due to the oxygen mask – when she went to meet him the next day. The note read: 'Subah director had come. Director said Chabra has done wrong tapping. It will be done again.' She attached the dying declaration as evidence in her case before the consumer forum. A spokesperson of the Fortis hospital said they are aware of a consumer case concerning their hospital. 'As we are yet to receive the official court order, we are unable to comment on the specifics at this stage. Once the order is in hand, we will conduct a thorough review and, guided by expert legal advice, take appropriate action as deemed necessary.'
